Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low molecular weight heparins

B Cosmi1, J Hirsh

  • 1Hamilton Civic Hospitals Research Centre, Ontario, Canada.

Current Opinion in Cardiology
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Low molecular weight heparins (LMWHs) offer improved bioavailability and predictability over unfractionated heparin (UFH). LMWHs show significant advantages in orthopedic surgery for preventing venous thromboembolism and are effective for treating deep vein thrombosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.

BMC infectious diseases·2023
Same author

Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register.

International journal of laboratory hematology·2018
Same author

External validation of the DASH prediction rule: a retrospective cohort study.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2016
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
Same journal

Advances in artificial intelligence for the evaluation of mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Role of nutritional interventions to reduce cardiometabolic disease burden in the community.

Current opinion in cardiology·2026
See all related articles

Area of Science:

  • Pharmacology
  • Biochemistry
  • Thrombosis Research

Background:

  • Low molecular weight heparins (LMWHs) are derived from unfractionated heparin (UFH) through depolymerization.
  • This process reduces mean molecular weight, enhancing biochemical and pharmacologic properties.

Purpose of the Study:

  • To compare the efficacy and safety of LMWHs versus UFH.
  • To evaluate LMWH advantages in various clinical settings, including surgical prophylaxis and deep vein thrombosis treatment.

Main Methods:

  • Review of clinical studies and experimental data comparing LMWH and UFH.
  • Analysis of pharmacokinetic properties, dose-response relationships, and clinical outcomes.

Main Results:

  • LMWHs demonstrate greater bioavailability, longer half-life, and more predictable dose response than UFH.

Related Experiment Videos

  • Clinical studies show modest advantages in general surgery but substantial benefits in orthopedic surgery for venous thromboembolism prevention.
  • LMWHs are as effective and safe as UFH for treating deep vein thrombosis, with added benefits of simpler administration and outpatient use.

    • Conclusions:

    • LMWHs offer significant therapeutic advantages over UFH, including improved pharmacokinetics and clinical efficacy.
    • The predictable response allows for fixed dosing without laboratory monitoring, enhancing patient management.
    • LMWHs represent a valuable therapeutic option for venous thromboembolism prophylaxis and treatment, particularly in orthopedic surgery and outpatient settings.